Alpha-MSH comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
While only some 6.4% of forests inside of legally declared protected areas were cleared between 1980 and 2010, over a quarter of forests outside of protected areas were lost between 1980 and 2010. As a country with a relatively high forest cover and a low deforestation rate, Belize has significant potential for participation in initiatives such as REDD. Significantly, the SERVIR study on Belize's deforestation was also recognized by the Group on Earth Observations (GEO), of which Belize is a member nation.
=== Associated conditions === A variety of patient factors can lead to CTS, including heredity, size of the carpal tunnel, associated local and systematic diseases, and certain habits. Non-traumatic causes generally happen over a period of time, and are not triggered by one certain event. Many of these factors are manifestations of physiologic aging.
====== MALDI ====== In matrix-assisted laser desorption and ionization (MALDI), the sample is incorporated in a chemical matrix that is capable of absorbing energy from a laser. Similar to SIMS, ionization happens in vacuum. Laser irradiation ablates the matrix material from the surface and results in charged gas phase matrix particles, with the analyte molecules ionized from this charged chemical matrix. Liu et al. used MALDI-MS to detect eight phospholipids from single A549 cells. MALDI MS imaging can be used for spatial metabolomics and single-cell analysis.
Sources: en.wikipedia.org
== History == The school was established by U.S. President Millard Fillmore in 1846. Buffalo was a boomtown on the Erie Canal and the gateway to the West. Leading citizens — primarily physicians and lawyers — proposed that an institution of higher learning be established, which led to the founding of the private, nonsectarian University of Buffalo. The Medical School, or Medical Department, as it was called, was the first decanal unit within the university, and 40 years passed before other departments were added. Medical classes began February 24, 1847, with an enrollment of 66 students. The medical school's first permanent location was next to Buffalo General Hospital in downtown Buffalo. In 1893, the school relocated to High Street in the city, where it remained until 1953, when it moved to the university's South Campus. It moved in 2017 to a new campus on High and Main Streets, again adjacent to the Buffalo General Hospital complex. In 1962, University of Buffalo merged with the State University of New York (SUNY) system. The Medical School then became the School of Medicine, State University of New York at Buffalo. Throughout its history, the university has not owned or operated a teaching hospital, but instead has instructed students in affiliated hospitals throughout the city. Today's network of teaching affiliations was formalized in 1983 as the Graduate Medical Dental Education Consortium of Buffalo.
=== Anabolic pathway (anabolism) === In contrast to catabolic pathways, anabolic pathways require an energy input to construct macromolecules such as polypeptides, nucleic acids, proteins, polysaccharides, and lipids. The isolated reaction of anabolism is unfavorable in a cell due to a positive Gibbs free energy (+ΔG). Thus, an input of chemical energy through a coupling with an exergonic reaction is necessary. The coupled reaction of the catabolic pathway affects the thermodynamics of the reaction by lowering the overall activation energy of an anabolic pathway and allowing the reaction to take place. Otherwise, an endergonic reaction is non-spontaneous. An anabolic pathway is a biosynthetic pathway, meaning that it combines smaller molecules to form larger and more complex ones. An example is the reversed pathway of glycolysis, otherwise known as gluconeogenesis, which occurs in the liver and sometimes in the kidney to maintain proper glucose concentration in the blood and supply the brain and muscle tissues with adequate amount of glucose. Although gluconeogenesis is similar to the reverse pathway of glycolysis, it contains four distinct enzymes(pyruvate carboxylase, phosphoenolpyruvate carboxykinase, fructose 1,6-bisphosphatase, glucose 6-phosphatase) from glycolysis that allow the pathway to occur spontaneously.
SR-17018 has been found to act as a non-competitive MOR agonist with nearly irreversible binding to the receptor, resulting in persistent G protein signaling. However, MOR antagonists like naloxone can still fully reverse MOR stimulation by SR-17018 and hence SR-17018 is not an insurmountable MOR agonist. These findings suggest that SR-17018 interacts with an allosteric site on the MOR to facilitate G protein signaling whilst allowing the receptor to remain sensitive to antagonists at the orthosteric site. There is said to be strong evidence for SR-17018 interaction with a MOR allosteric site and its mechanism of MOR activation in vivo may be predominantly noncompetitive, but SR-17018 appears to interact with both this allosteric site and with the orthosteric site of the MOR. On the other hand, SR-17018 can antagonize certain morphine-induced effects in vivo, suggesting possible MOR competitive interaction. SR-17018 produces potent and strong analgesic effects in rodents similarly to other MOR agonists like morphine and fentanyl. Conversely, the drug produces very little respiratory depression in rodents. It was estimated that the mouse therapeutic window, or quotient of respiratory depression and analgesia, was 26 to 105 for SR-17018, relative to 5 to 21 for morphine and 2 to 5 for fentanyl. This was based on median effective dose (ED50) findings in oxygen saturation and breath rate assays divided by those in the hot plate and tail-flick tests.
Sources: en.wikipedia.org
=== 1940s === During and after World War II, the field of biomedical science saw a new age of technology and treatment methods. For instance in 1941 the first hormonal treatment for prostate cancer was implemented by Urologist and cancer researcher Charles B. Huggins. Huggins discovered that if you remove the testicles from a man with prostate cancer, the cancer had nowhere to spread, and nothing to feed on thus putting the subject into remission. This advancement lead to the development of hormonal blocking drugs, which is less invasive and still used today. At the tail end of this decade, the first bone marrow transplant was done on a mouse in 1949. The surgery was conducted by Dr. Leon O. Jacobson, he discovered that he could transplant bone marrow and spleen tissues in a mouse that had both no bone marrow and a destroyed spleen. The procedure is still used in modern medicine today and is responsible for saving countless lives.
Phenadoxone (trade names Heptalgin, Morphidone, and Heptazone) is an opioid analgesic of the open chain class (methadone and relatives) invented in Germany by Hoechst in 1947. It is one of a handful of useful synthetic analgesics which were used in the United States for various lengths of time in the 20 or so years after the end of the Second World War but which were withdrawn from the market for various or no known reason and which now are mostly in Schedule I of the United States' Controlled Substances Act of 1970, or (like phenazocine and bezitramide) in Schedule II but not produced or marketed in the US. Others on this list are ketobemidone (Ketogin), dextromoramide (Dimorlin, Palfium and others), phenazocine (Narphen and Prinadol), dipipanone (Diconal, Pipadone and Wellconal), piminodine (Alvodine), propiram (Algeril), anileridine (Leritine) and alphaprodine (Nisentil). Phenadoxone has a US DEA ACSCN of 9637 and has had a zero annual manufacturing quota under the Controlled Substances Act 1970. Its withdrawal from US distribution prior to the promulgation of said act is a large part of its Schedule I designation; it is, however, used as a legitimate medication in other countries and consumption is increasing worldwide as indicated below. Phenadoxone is generally considered to be a strong opioid analgesic and is regulated in much the same way as morphine where it is used. The usual starting dose is 10–20 mg and it has a duration of analgesic effect of 1 to 4 hours. Phenadoxone is not used at this time for purposes other than pain relief.
SDMA, also known as 3,4-methylenethiooxy-N-methylamphetamine (3T-MDMA) or as MY100, is a putative entactogen of the phenethylamine and amphetamine families related to 3,4-methylenedioxy-N-methylamphetamine (MDMA). It is the analogue of MDMA in which the oxygen atom at the 3 position within the 3,4-methylenedioxy substitution has been replaced with a sulfur atom to give a 1,3-benzoxathiole rather than 1,3-benzodioxole ring system. The drug is also the N-methyl derivative of 3,4-methylenethiooxyamphetamine (SDA; 3T-MDA). SDMA is of interest for potential therapeutic use.
=== Diabetes === There are numerous theories as to the exact cause and mechanism in type 2 diabetes. Central obesity is known to predispose individuals for insulin resistance. Abdominal fat is especially active hormonally, secreting a group of hormones called adipokines that may possibly impair glucose tolerance. But adiponectin, an anti-inflammatory adipokine, which is found in lower concentration in obese and diabetic individuals has shown to be beneficial and protective in type 2 diabetes mellitus (T2DM). Insulin resistance is a major feature of diabetes mellitus type 2, and central obesity is correlated with both insulin resistance and T2DM itself. Increased adiposity (obesity) raises serum resistin levels, which in turn directly correlate to insulin resistance. Studies have also confirmed a direct correlation between resistin levels and T2DM. And it is waistline adipose tissue (central obesity) which seems to be the foremost type of fat deposits contributing to rising levels of serum resistin. Conversely, serum resistin levels have been found to decline with decreased adiposity following medical treatment.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.